SOURCE-LINKED STUDY SUMMARY
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
Abstract summarizedQuality not appraised
- What was studied
- Double-blind randomized phase 2 trial of MariTide, a long-acting GLP-1 agonist/GIP-receptor antagonist, for weight loss.
- Who / model studied
- 592 adults: 465 with obesity without diabetes and 127 with obesity and type 2 diabetes.
- Studied dose & schedule
- 52 weeks; subcutaneous 140, 280 or 420 mg every 4 weeks versus placebo. Obesity-only arms also tested 420 mg every 8 weeks or 420 mg every 4 weeks with 4- or 12-week escalation.
- What the study found
- Treatment-policy weight change across regimens: −12.3% to −16.2% versus −2.5% placebo without diabetes; −8.4% to −12.3% versus −1.7% with diabetes. Diabetes-cohort HbA1c changed −1.2 to −1.6 percentage points versus +0.1.
- Limitations & context
- Gastrointestinal events were common, less frequent with escalation and lower starting doses. Abstract assessment; dose-specific weight-loss estimates and event rates were not supplied.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa2504214